{
    "clinical_study": {
        "@rank": "159949", 
        "acronym": "REACH", 
        "arm_group": {
            "arm_group_label": "Renal denervation", 
            "arm_group_type": "Experimental", 
            "description": "renal denervation"
        }, 
        "brief_summary": {
            "textblock": "Renal denervation can be carried out for heart failure"
        }, 
        "brief_title": "Renal Denervation in Chronic Heart Failure", 
        "completion_date": {
            "#text": "February 2012", 
            "@type": "Actual"
        }, 
        "condition": "Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "detailed_description": {
            "textblock": "There are theoretical reasons why renal denervation might be beneficial for patients with\n      chronic heart failure. It is not known whether they would suffer large drops in blood\n      pressure which might compromise safety.\n\n      This pilot study required patients to remain in hospital for one week during which they had\n      careful monitoring of blood pressure with the ability to halt the trial if any patient\n      suffered any dangerous effect such as a large drop in blood pressure. It also monitored\n      blood pressure after discharge for six months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        -Patients were required to have chronic symptomatic systolic heart failure (NYHA class III\n        or IV) on maximal tolerated medical therapy, including beta-blocker, ACE inhibitor or\n        angiotensin receptor blocker, and spironolactone.\n\n        Exclusion Criteria:\n\n          -  Clinically unstable patients or those with significant valvular disease\n\n          -  An estimated glomerular filtration rate <35 ml/min\n\n          -  Unfavourable renal anatomy\n\n          -  Tortuous femoral arteries were not eligible"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "7", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02146794", 
            "org_study_id": "ICCH-10/065"
        }, 
        "intervention": {
            "arm_group_label": "Renal denervation", 
            "description": "Renal denervation", 
            "intervention_name": "Renal denervation", 
            "intervention_type": "Device", 
            "other_name": "Symplicity Renal Denervation System"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 21, 2014", 
        "number_of_arms": "1", 
        "official_title": "Renal Denervation in Chronic Heart Failure", 
        "other_outcome": {
            "measure": "Left ventricular ejection fraction by Echocardiography", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "overall_official": [
            {
                "affiliation": "Imperial College London", 
                "last_name": "Darrel P Francis, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Imperial College London", 
                "last_name": "Justin E Davies, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: National Health Service", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Renal denervation had been reported to cause a 30 mmHg fall in blood pressure when used in hypertension. Although in principle renal denervation might be favourable for physiology in chronic heart failure, numerous theoretical possibilities exist for the procedure causing deterioration in clinical status, including the possibility of  a large fall in blood pressure.\nA deterioration in symptomatic status or occurrence of an event such as presyncope or syncope would be considered a primary outcome event.", 
            "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "reference": [
            {
                "PMID": "24603957", 
                "citation": "Shun-Shin MJ, Howard JP, Francis DP. Removing the hype from hypertension. BMJ. 2014 Mar 6;348:g1937. doi: 10.1136/bmj.g1937. Erratum in: BMJ. 2014;348:g2088."
            }, 
            {
                "PMID": "24480181", 
                "citation": "Howard JP, Cole GD, Sievert H, Bhatt DL, Papademetriou V, Kandzari DE, Davies JE, Francis DP. Unintentional overestimation of an expected antihypertensive effect in drug and device trials: mechanisms and solutions. Int J Cardiol. 2014 Mar 1;172(1):29-35. doi: 10.1016/j.ijcard.2013.12.183. Epub 2014 Jan 8."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02146794"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "23031283", 
            "citation": "Davies JE, Manisty CH, Petraco R, Barron AJ, Unsworth B, Mayet J, Hamady M, Hughes AD, Sever PS, Sobotka PA, Francis DP. First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int J Cardiol. 2013 Jan 20;162(3):189-92. doi: 10.1016/j.ijcard.2012.09.019. Epub 2012 Sep 29."
        }, 
        "secondary_outcome": [
            {
                "description": "Monitored as inpatient for 5 days, then as outpatient for 6 months", 
                "measure": "Systolic blood pressure", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Serum Creatinine", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Serum sodium", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Serum potassium", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "6 minute walk distance", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Imperial College London", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Imperial College London", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2011", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}